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Abstract: Although widely used in lipid lowering therapy, HMG CoA reductase inhibitors (even 
when administered at high doses) are frequently insufﬁ  cient to achieve guideline-recommended 
LDL-C goals for many patients with hypercholesterolemia in everyday clinical practice. Many 
patients do not achieve LDL-C goal on the initial dose of statin and the majority of these 
patients does not reach their goal after 6 months. As a consequence, a wide therapeutic gap 
exists between target LDL-C levels and those typically achieved in clinical practice. A recent 
and more effective therapeutic hypocholesterolemic strategy is to treat the two main sources 
of cholesterol simultaneously (production of cholesterol, mainly in the liver, and absorption of 
cholesterol in the intestine) with a complementary mechanism of action, by co-administering 
ezetimibe, a novel agent inhibiting cholesterol absorption, with a statin, which inhibits choles-
terol production in the liver. Ezetimibe can be effectively and safely co-administered with any 
dose of any statin and, compared with the single inhibition of cholesterol production, afforded 
by statins alone, provides consistently greater reductions in LDL-C through dual inhibition of 
both cholesterol production and absorption. We summarize the pivotal role of both the liver 
and intestine in the overall balance of cholesterol in the body and describe the clinical impact 
and relevance of using ezetimibe either alone or co-administered with statins in controlling 
elevated levels of plasma LDL cholesterol.
Keywords: hypercholesterolemia, cholesterol absorption, cholesterol biosynthesis, ezetimibe, 
HMG CoA reductase inhibitors, LDL-C
Introduction
Hypercholesterolemia plays a key role in the development and progression of athero-
sclerosis and is a proven risk factor for coronary heart disease (CHD) (Wilson 1980; 
Stamler 1986; Steinberg 1990; Castelli 1992). Therapeutic interventions aimed at 
lowering cholesterol levels both in primary and secondary prevention show a clear 
reduction in the incidence of CHD and stroke (Anon 1984; Manninen et al 1988; Frick 
et al 1987; Anon 1994; Sheperd et al 1995; Downs et al 2001; Collins 2004).
Although widely used in lipid lowering therapy, HMG CoA reductase inhibitors 
(even when administered at high doses) are frequently insufﬁ  cient to achieve guideline-
recommended low-density lipoprotein cholesterol (LDL-C) goals for many patients with 
hypercholesterolemia in everyday clinical practice (Goettsch et al 2004). According to a 
recent study, a large proportion of high-risk hyperlipidemic patients receiving statins alone 
are not at goal even when physicians were free to use any statin and titrate according to 
their professional judgment (Foley et al 2003). Over half (52%) of patients did not achieve 
LDL-C goal on the initial dose of statin, and 86% of these patients had still not reached 
goal after 6 months (Foley et al 2003). Thus, a wide therapeutic gap exists between target 
LDL-C levels and what is achieved in clinical practice (Neal et al 2003).
The therapeutic gap will undoubtedly increase in light of the recent amendments 
of the National Cholesterol Education Program Adult Treatment Program III (NCEP Vascular Health and Risk Management 2008:4(2) 268
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ATP III) guidelines, which recommend even more aggressive 
reductions in LDL-C levels for patients at high risk of CHD 
(Grundy et al 2004). The more aggressive cholesterol treat-
ment goals proposed by the revised guidelines call for a more 
effective approach to maximize the cardiovascular beneﬁ  ts 
associated with lower LDL-C levels.
In the human body there are two major sources of 
cholesterol: ﬁ  rst, the gastrointestinal tract where daily cho-
lesterol is derived from the diet, bile input and desquamated 
cells (Levy et al 2007); second, the liver which is the major 
source of cholesterol synthesis; in the human body (Goldstein 
et al 1990). Approximately 50% of the cholesterol pool is 
absorbed and recirculated through the intestine, while the 
remainder is excreted through the feces (Lammert et al 
2005; Wang et al 2007). The intestinal pool is composed 
of both dietary, and the majority, from biliary excretion. A 
recent and more effective therapeutic strategy, is to treat both 
sources of cholesterol simultaneously with a complementary 
mechanism of action, by co-administering ezetimibe, a novel 
agent inhibiting cholesterol absorption, together with a statin, 
which inhibits cholesterol production in the liver (Lammert 
et al 2005; Levy et al 2007; Wang et al 2007). This results 
in dual inhibition of both sources of cholesterol provides 
signiﬁ  cantly greater LDL-C reduction and subsequent goal 
attainment.
Ezetimibe can be effectively co-administered with any 
dose of any statin; indeed the beneﬁ  ts are consistent across 
the statin brand and dose subgroups and compared with single 
inhibition of cholesterol production, afforded by statins alone, 
provides consistently greater reductions in LDL-C through 
dual inhibition of both cholesterol production and absorp-
tion (Gagne et al 2002; Ballantyne et al 2003; Kerzner et al 
2003; Melani et al 2003; ) The single product of ezetimibe/
simvastatin provides superior LDL-C lowering efﬁ  cacy with 
improved LDL-C goal attainment (Ballantyne et al 2004; 
Feldman et al 2004; Ballantyne et al 2005).
Here we summarize the pivotal role of both the liver and 
intestine in the overall balance of cholesterol in the body and 
describe the clinical impact and relevance of inhibiting both 
sources of cholesterol.
The liver and intestine: two sources 
of cholesterol
The average adult body contains approximately 140 g of 
sterols, mainly in the form of cholesterol (Cook et al 1958). 
This pool of cholesterol is derived from two major sources: 
synthesis of cholesterol by the liver (and extrahepatic sites) 
and absorption by the intestines (Goldstein et al 1990; Levy 
et al 2007). Approximately 500–1400 mg/day of cholesterol 
enters the body’s cholesterol pool from synthesis (500–1000 
mg) and diet (up to 500 mg/day) (Cook et al 1958; Illingworth 
et al 1995). However, the cholesterol pool usually changes 
little because cholesterol input is approximately balanced by 
cholesterol output via excretion in bile/feces, skin excretion, 
steroid hormone synthesis, etc (Cook et al 1958; Illingworth 
et al 1995).
The liver plays a central role in balancing cholesterol 
from all sources and also plays pivotal role in regulating 
plasma LDL-C levels (Dietschy et al 1993). The hepatic 
pool of cholesterol is derived from local biosynthesis and 
from chylomicron remnants and lipoproteins. Cholesterol 
biosynthesis is regulated by the rate-limiting enzyme HMG 
CoA reductase, which catalyzes production of mevalonic 
acid from HMG CoA and represents the therapeutic target 
for statins. Cholesterol produced by liver is either secreted 
in bile or incorporated into lipoproteins (mainly VLDL) and 
secreted into plasma.
Intestinal cholesterol absorption represents another major 
route for the entry of cholesterol into the body, and, thus, 
this source can inﬂ  uence LDL-C concentration (Wang et al 
2007). Daily the cholesterol pool in the intestine comes from 
either dietary cholesterol (300–500 mg), from biliary excre-
tion (800–1200 mg) and from desquamated cells (300 mg) 
(Lammert et al 2005; Wang et al 2007). Of note, as a large 
part of the cholesterol absorbed results from the reabsorbtion 
of cholesterol excreted through the bile, it is appropriate to 
talk about entero-hepatic recirculation). The excess choles-
terol is then excreted through the feces. Although the details 
of the molecular transport of cholesterol absorption are not 
fully understood, it is clear that cholesterol absorption in the 
intestine involves a complex triphasic process (Figure 1): 
intraluminal phase (digestion/hydrolysis of dietary lipids and 
micellar solubilization of cholesterol), membrane transport 
phase (cholesterol release from micelles at brush border 
membrane and uptake into enterocytes), and an intracel-
lular phase (re-esteriﬁ  cation, incorporation into nascent 
chylomicrons, and secretion into lymph) (Lammert et al 
2005; Wang et al 2007). Cholesterol appears to be speciﬁ  -
cally removed from the micelles as part of the absorption 
process: it is absorbed mainly in the duodenum and jejunum, 
but bile acids are not absorbed to an appreciable degree at 
these sites. Rather, speciﬁ  c bile acid transporters located in 
the ileum subsequently absorb bile acids, delivering them 
back to the liver and thus giving rise to an enterohepatic 
circulation (Levy et al 2007). Until recently non-cholesterol 
sterols were not thought to be absorbed during this process; Vascular Health and Risk Management 2008:4(2) 269
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however, new insights into sitosterolemia or phytosterolemia, 
a rare autosomal recessive disorder caused by hyperabsorp-
tion and impaired biliary secretion of cholesterol and plant 
sterols, which subsequently accumulate in tissues causing 
tendon xanthoma and premature coronary artery disease, 
have depicted a different situation. The disease appears to 
be produced by mutations in two half-size ABC transporters, 
ABCG5 and ABCG8, localized at the apical membrane of 
the enterocyte and at the canalicular membrane in the liver. 
When functional, these transporters unite to form a full, active 
transporter and limit the absorption of both plant sterols and 
cholesterol by actively pumping them from enterocytes back 
into the intestinal lumen. These transporters may also pro-
mote the elimination of sterols in the liver by enhancing their 
excretion into bile. Mice lacking abcg5/abcg8 genes mimic 
the major phenotypes of human sitosterolemia (Salen et al 
1992). A key protein involved in cholesterol absorption is 
NPC1L1, which has been found to be abundantly expressed in 
small intestine particularly in the jejunum at the brush-border 
membrane but also is present in subcellular compartments of 
human enterocyte, including lysosomes and mitochondria. 
NPC1L1 was ﬁ  rst described in 2000 (Davies et al 2000); 
its name derives from the fact that it shares 42% amino 
acid identity with Niemann-Pick type C1 protein (NPC1), a 
protein involved in intracellular cholesterol transport and is 
also the causative gene for Niemann-Pick disease type C1 
(Carstea et al 1997). In mouse, rat, and human, the small 
intestine showed a high level of NPC1L1 mRNA expres-
sion (Altmann et al 2004) (Figure 1). With the exception 
of human liver, which showed similar levels of expression 
as the intestine, NPC1L1 expression in all other tissues was 
 10% of intestinal expression and was barely detectable in 
many tissues, in contrast with the fairly ubiquitous tissue 
expression of NPC1. Further analysis of the duodenal-ileal 
axis of rat small intestine demonstrated that peak expression 
of Npc1L1 mRNA and NPC1L1 protein occurred in the 
proximal jejunum, which was also the predominant site for 
sterol absorption (Altmann et al 2004).
The observation that mice lacking NPC1L1 have a mark-
edly reduced sterol absorption conﬁ  rmed the fundamental 
role of this protein as a cholesterol transporter in human 
enterocytes. After absorption, free cholesterol and fatty 
acids are re-esteriﬁ  ed in the enterocyte by the action of acyl-
coenzyme A:cholesterol acyl-transferase (ACAT), packaged 
with triglycerides, phospholipids and apolipoprotein B-48 
into chylomicrons, and ﬁ  nally secreted from the basolateral 
site of the enterocytes from where they enter the lymphatic 
channels and eventually are transported into the peripheral 
circulation (Wang et al 2007). Recent studies have signiﬁ  -
cantly advanced our understanding of intestinal sterol absorp-
tion at the molecular level. Two nuclear hormone receptors 
are believed to be involved in the regulation of cholesterol 
homeostasis, the liver X receptor (LXR) and the farnesoid 
X receptor (FXR). The natural ligands for LXR and FXR 
Figure 1 Cholesterol absorption in NPC1L1 (–/–) mice and in (+/+) mice treated with ezetimibe. Drawn from data of Altmann et al (2004); Garcia-Calvo et al (2005).
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are oxysterols (oxidized derivatives of cholesterol) and bile 
acids, respectively (Russell et al 1999).
To modulate transcriptional activity, ligand-activated 
LXR or FXR form a heterodimer with one additional nuclear 
hormone receptor, the retinoid X receptor (RXR). These 
heterodimers control the transcription of several important 
genes that participate into cholesterol metabolism, some-
times appearing to antagonize the effects of each other. 
Two mechanism are involved in the reduction of choles-
terol following FXR-RXR and LXR-RXR activation (Repa 
et al 2000, 2002). The FXR-RXR heterodimer suppresses 
CYP7A1 expression and decreases bile acid synthesis. 
Because non-polar lipids such as cholesterol have a limited 
solubility in the aqueous environment of the intestinal lumen, 
bile acids are required to solubilize these non-polar com-
pounds and allow their absorption. By suppressing bile acid 
production, the activated FXR-RXR heterodimer decreases 
the solubilization and absorption of dietary cholesterol. Even 
though activation of the LXR-RXR heterodimer could not 
counterbalance the FXR-RXR–mediated suppression of 
CYP7A1 expression, the activated LXR-RXR heterodimer 
has a powerful effect on cholesterol homeostasis by inducing 
the expression of ABC transporters (speciﬁ  cally, ABCA1) 
in enterocytes. This increase in ABCA1 expression repre-
sents the second mechanism by which the administration of 
the RXR ligand decreases cholesterol absorption. ABCA1 
normally pumps cholesterol from enterocytes back out to the 
intestinal lumen, thereby limiting the amount of cholesterol 
absorbed (Repa et al 2000; Brewer and Santamarina-Fojo 
2003). Indeed, mice treated with the RXR ligand present 
an increased intestinal expression of ABCA1, mediated by 
the activation of the LXR-RXR heterodimer. Given these 
ﬁ  ndings, pharmacological activation of the nuclear hormone 
receptors RXR, LXR and FXR, including PPARs agonist 
that have been shown to positively affect LXR expression 
and activity, may represent a treatment option for hyper-
cholesterolemia.
Mechanism of action of ezetimibe
In the past few years, an innovative approach to cholesterol-
lowering therapy has been introduced. Ezetimibe is the ﬁ  rst 
in a class of cholesterol-lowering agents with a mechanism 
of action that is very different from other lipid lowering 
therapies, including bile acid sequestrants.
By inhibiting cholesterol absorption at the level of the 
brush border of the intestine, ezetimibe reduces the amount of 
lipoprotein cholesterol circulated to the liver. In response to 
reduced cholesterol delivery, the liver reacts by upregulating 
LDL-C receptors, which in turn leads to increased clearance 
of cholesterol from the blood (Lammert et al 2005).
A major advance in the understanding of ezetimibe’s 
mechanism of action occurred in 2004 when Altmann and 
colleagues evaluated sequence data from human, rat, and 
mouse gastrointestinal cDNA libraries to identify proteins 
with features, such as transmembrane domains and known 
cholesterol sensing motifs, that would be expected to be seen 
in a putative cholesterol transporter (Altmann et al 2004).
Interestingly, ezetimibe has also been shown to block 
the uptake of oxidized LDL by human macrophages through 
inhibition of both NPC1L1 and ANX2/CAV1 (Seedorf et al 
2004; Levy et al 2007), suggesting the actions of this agent 
may extend beyond the intestinal epithelium. Aminopepti-
dase N (CD13) in the brush border membrane may represent 
an additional molecular target for ezetimibe. Ezetimibe has 
been shown to bind to aminopeptidase N thereby blocking 
the endocytosis of cholesterol from micelles in the intestinal 
lumen (Levy et al 2007). Additional evidence has come from 
in vitro binding assays that tested directly the interaction 
between the drug and NPC1L1. Garcia-Calvo, with Davis, 
Thornbury, and colleagues (Garcia-Calvo et al 2005) devel-
oped a binding assay and showed that labeled ezetimibe 
glucuronide bound speciﬁ  cally to a single site in intestinal 
epithelial brush border membranes and in embryonic kidney 
cells engineered to express NPC1L1. Furthermore, the bind-
ing afﬁ  nities of ezetimibe and its analogs to recombinant 
NPC1L1 were indistinguishable from those observed for 
native enterocyte membranes. Values for the dissocia-
tion constant of ezetimibe glucuronide for NPC1L1 were 
evaluated in intestinal enterocyte membranes and human 
embryonic kidney cells engineered to express NPC1L1 from 
various species. Binding afﬁ  nities were highest for rhesus 
monkey compared with more moderate values for rat and 
human, with the lowest values reported for mouse, which 
also correlates well with the in vivo potency observed for 
ezetimibe across species. Also, ezetimibe failed to affect 
cholesterol absorbtion in Npc1L1–/– null mice compared with 
wild-type mice (Figure 2). These results established NPC1L1 
as the target for the action of ezetimibe.
Ezetimibe is rapidly metabolized in the intestine to its 
phenolic glucuronide; once glucuronidated, it is excreted in the 
bile, thereby delivering the drug back to the main site of action. 
Cholesterol absorption studies indicated that the glucuronide 
appeared more potent than ezetimibe itself, and this is likely 
because glucuronidated ezetimibe localizes more avidly to the 
intestine. Autoradiographic analysis demonstrated that drug-
related material was located throughout the intestinal villi but Vascular Health and Risk Management 2008:4(2) 271
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concentrated in the villus tip. In humans, ezetimibe is rapidly 
absorbed and primarily metabolized in the small intestine and 
liver to its glucuronide, with little oxidative cytocrome P450 
mediated metabolism (Patrick et al 2002). Ezetimibe and its 
glucuronide undergo enterohepatic recycling and have a half-
life of approximately 24 hours in humans. Ezetimibe and/or 
the glucuronide metabolite are excreted in the feces (90%) and 
urine (10%). Since ezetimibe does not inﬂ  uence the activities of 
cytocrome P450 enzymes, signiﬁ  cant pharmacokinetic interac-
tions with many medications have not been noted. Pharmaco-
kinetic interaction studies of ezetimibe in humans have found 
no signiﬁ  cant changes in the plasma levels of other medications 
including statins (atorvastatin, simvastatin, pravastatin, lovas-
tatin, and ﬂ  uvastatin), ﬁ  brates (gemﬁ  brozil and fenoﬁ  brate), 
digoxin, glipizide, warfarin and oral contraceptives (ethinyl 
estradiol and levonorgestrel (Kosoglou et al 2005).
Treating two sources of cholesterol: 
co-administering ezetimibe 
together with a statin
Statins (eg, ﬂ  uvastatin, lovastatin, pravastatin, simvastatin, 
atorvastatin, and rosuvastatin) deliver only single inhibition 
of cholesterol production in the liver by blocking HMG-Co A 
reductase, the rate-limiting step in cholesterol synthesis, but 
do not impact signiﬁ  cantly intestinal cholesterol absorption 
(Shepherd et al 2004). As a result, hepatocytes become 
depleted of cholesterol and respond by increasing LDL-C 
clearance from the blood (via upregulation of hepatic LDL-C 
receptors) and decreasing entry of LDL-C into the circula-
tion. These actions, in turn, result in the lowering of plasma 
LDL-C levels. Of note HMGCoA reductase inhibitors could 
target also cholesterol synthesis in the ileum (Parker et al 
1990; Sviridov et al 1990); therefore reduced cholesterol bio-
synthesis in the small intestine by statins may also contribute 
to the reduction of plasma cholesterol concentrations.
The use of two lipid-lowering compounds (ezetimibe 
co-administered with a statin) with complementary mecha-
nisms of action provides a powerful new approach to prevent 
and treat atherosclerosis. Treating two sources of cholesterol 
(rather than one source with statins or ezetimibe alone) 
results in a substantially greater overall LDL-C lowering 
efﬁ  cacy as well as in more patients attaining or getting 
below LDL-C goals.
Ezetimibe added to a statin has the potential to lower 
cholesterol by dual inhibition of both cholesterol absorption 
Figure 2 Overview of the principal steps in the intestinal absorption of cholesterol (C). The intraluminal phase involves the digestion/hydrolysis of dietary lipids and micel-
lar solubilization of cholesterol. The membrane transport phase involves cholesterol release from micelles at the brush border membrane and uptake into enterocytes via 
several sterol transporters, including Niemann-Pick C1like 1 protein (NPC1L1), aminopeptidase N (CD13), and annexin-2/caveolin-1 (ANX2/CAV1). The brush border 
membrane also contains ATP-binding cassette (ABC) transporters (ABCG5 and ABCG8), which primarily move plant sterols and to a lesser extent cholesterol out of the 
enterocytes.
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and cholesterol synthesis. Adding ezetimibe to ongoing 
statin therapy led to a substantial additional reduction in 
LDL cholesterol levels, facilitating attainment of NCEP 
goals. In patients with hypercholesterolemia not at goal 
on statin therapy alone, the Ezetimibe Add-On to Statin 
for Effectiveness (EASE) trial (Pearson et al 2004; Denke 
et al 2006) demonstrated that co-administering ezetimibe 
(10 mg) with any dose of statin reduced LDL-C levels by 
an additional 25%, compared with the usual 6% attained 
by doubling the statin dose and improved LDL-C goal 
attainment from 20% on statin monotherapy to 71% vs 
18.9% on statin alone, p   0.001 (Gagne et al 2002) 
(Figures 3 and 4).
The beneﬁ  ts were consistent across the statin brand and 
dose subgroups, in particular association of ezetimibe with 
atorvastatin (10–80 mg), ﬂ  uvastatin (20–80 mg), lovastatin 
(20–80 mg), pravastatin (10–80 mg), simvastatin (10–80 mg) 
was studied (Denke et al 2006).
Ezetimibe when co-administered with a statin was 
signiﬁ  cantly better than placebo in increasing high-density 
lipoprotein cholesterol (HDL-C) and reducing triglycer-
ides, non-HDL-C, and apolipoprotein B (p   0.001 for 
all between-treatment differences). The superior reduction 
in LDL-C with ezetimibe compared with placebo was 
consistent across all ages, in men and women, and all 
ethnicities. Patients with diabetes or metabolic syndrome 
(including those with or without diabetes) who were 
randomized to ezetimibe had superior reduction in LDL-C 
compared with placebo. The superior LDL-C reduction 
with ezetimibe was consistent when analyzed by statin 
brand and statin dose.
Other lipid parameters statistically improved with the 
addition of ezetimibe were: ratios of LDL-C/HDL-C, of 
total cholesterol/HDL-C and non-HDL-C. Finally C-reactive 
protein, a non-speciﬁ  c inﬂ  ammatory marker associated with 
cardiovascular risk, was further reduced by 12%.
Many studies have centered on the use of ezetimibe/
simvastatin as a single tablet: the association was superior 
to atorvastatin alone in reducing plasma LDL-C at every 
dose comparison studied, according to double-blind, 
randomized, forced-titration study (Ballantyne et al 2004). 
Adult patients with hypercholesterolemia experienced 
significantly greater reductions in LDL-C when they 
received the typical starting dose of ezetimibe/simvastatin 
10/20 mg (50%) compared with atorvastatin 10 mg (37%) 
after 6 weeks of treatment (p   0.001). Interestingly, the 
reduction in LDL-C levels seen with the association was 
comparable to the 50% reduction in LDL-C levels that 
has shown to be required for reversal of IVUS-evidenced 
atherosclerosis (Pearson et al 2004). In addition, ezetimibe/
simvastatin resulted in significantly more patients 
achieving LDL-C goal ( 100 mg/dL) whether compared 
with atorvastatin or simvastatin alone (Feldman et al 2004; 
Ballantyne et al 2005) (Figure 5).
Figure 3 Ezetimibe Add-On to Statin for Effectiveness study: percentage changes in LDL-C overall and by NCEP CHD risk category (n = 3030). Drawn from data of 
Pearson et al (2005).
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Figure 4 Ezetimibe Add-On to Statin for Effectiveness study: LDL-C goal attainment for patients (n = 3030) not at goal at baseline. Drawn from data of Pearson et al (2005).
Figure 5 Vytorin Versus Atorvastatin Study: Achievement of LDL-C  100 mg/dL in patients with CHD risk equivalent. Drawn from data of Ballantyne et al (2005).
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Further, compared with patients receiving atorvastatin 
alone, more patients treated with ezetimibe/simvastatin 
reached the more aggressive LDL-C target ( 70 mg/dL), as 
recently recommended by the NCEP for very high-risk CHD 
patients (Ballantyne et al 2005) (Figure 6). Approximately 
23% of patients receiving atorvastatin 40 mg alone and 36% 
of patients receiving atorvastatin 80 mg alone reached the 
optional LDL-C treatment target of  70 mg/dL compared 
with 57% of patients treated with ezetimibe/simvastatin 
(10/40 mg) and 64% of patients receiving ezetimibe/simv-
astatin (10/80 mg) (Ballantyne et al 2005).
The treatment with the usual starting doses of ezetimibe/
simvastatin 10/20 mg resulted in a 51% reduction of LDL-C 
compared to 36% reduction of LDL-C with the starting dose 
of atorvastatin 10 mg (Figure 7).
Similar data were observed in patients treated with 
ezetimibe/simvastatin compared to rosuvastatin (Catapano 
et al 2006); patients receiving ezetimibe/simvastatin had sta-
tistically signiﬁ  cantly greater reductions in lowering LDL-C 
at all doses and across doses (52%–61%) compared with a 
potent statin monotherapy agent, rosuvastatin, (46%–57%; 
p   0.001) at the usual starting, next highest, and maximum 
doses (Figure 8).
Signiﬁ  cantly higher percentages of patients achieved 
LDL-C levels of  100 mg/dL (2.6 mmol/L) with ezetimibe/
simvastatin versus rosuvastatin.
Furthermore, the greater LDL-C reducing efficacy 
produced by ezetimibe/simvastatin generally resulted in a 
higher percent of LDL-C goal attainment, particularly for 
those high-risk patients who attained LDL-C levels  70 mg/
dL ( 1.8 mmol/L). Patients treated with ezetimibe/sim-
vastatin versus rosuvastatin showed signiﬁ  cantly greater 
improvements in TC, apo B, non-HDL-C, and LDL-C:HDL-C 
and TC:HDL-C ratios at all dose comparisons, and also in 
TG at the usual starting doses (10/20 mg versus 10 mg), the 
maximum doses (10/80 mg versus 40 mg), and when averaged 
across all doses. Improvements in HDL-C and hsCRP were 
similar for both study medications at all dose comparisons. 
The EXPLORER study evaluated whether the association 
of rosuvastatin 40 mg with ezetimibe 10 mg enables more 
high-risk patients to achieve the LDL target compared with 
rosuvastatin monotherapy. This study demonstrated that the 
addition of ezetimibe increased goal achievement to 94% 
with 70% mean reduction in LDL-C (Ballantyne et al 2006). 
Similar results were obtained in another small study, in severe 
hyperlipidemic patients, resistant to 40 mg rosuvastatin 
monotherapy. LDL-C levels were reduced by 51% with the 
association rosuvastatin 40 mg/ezetimibe 10 mg, 45% of the 
patients achieved LDL-C values below 100 mg/dL (Leibovitz 
et al 2006). The VYTAL study compared the efﬁ  cacy and 
safety of the recommended usual starting and next highest 
doses of ezetimibe/simvastatin and atorvastatin in patients 
with diabetes mellitus and hypercholesterolemia (Goldberg 
et al 2006). The association of ezetimibe/simvastatin provided 
signiﬁ  cantly greater mean reduction in LDL-cholesterol levels 
10/20 mg (−54%) vs atorvastatin 10 mg (–38%, p   0.001) 
Figure 6 Vytorin Versus Atorvastatin Study: Achievement of LDL-C  70 mg/dL in patients with CHD risk equivalent. Drawn from data of Ballantyne et al (2005).
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Figure 7 Vytorin Versus Atorvastatin Study: LDL-C reductions. Drawn from data of Ballantyne et al (2005).
Figure 8 LDL-C reduction across the dose range. Drawn from data of Catapano et al (2006).
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or 20 mg (−45%, p   0.001) and with ezetimibe 10/40 mg 
(–58%) vs atorvastatin 40 mg (–51%, p   0.001). Ezetimibe/
simvastatin was also superior to atorvastatin in attainment of 
LDL-cholesterol levels less than 70 mg/dL (p   0.001 for all 
doses comparisons).
When administered in monotherapy, ezetimibe 10 mg/die 
showed a similar adverse events (AE) proﬁ  les compared to 
placebo (Dujovne et al 2002). Most of the adverse events (AEs) 
were judged by the investigators to be mild or moderate at 
their greatest intensity. Overall a similar percentage of patients 
Treatment comparison at each dose and averaged across doses
*p < 0.001 for all pairwise comparisons
-47.1*
-50.6*
-57.4*
-58.6*
-53.4*
-43.7
-48.3
-52.9
-45.3
-36.1
-60
-55
-50
-45
-40
-35
-30
Averaged
Across Doses
Eze/Simva Atorvastatin
P
e
r
c
e
n
t
C
h
a
n
g
e
(
±
S
E
)
F
r
o
m
B
a
s
e
l
i
n
e
i
n
L
D
L
-
C
(
m
g
/
d
L
)
10 mg                   20 mg                    40 mg                    80 mgVascular Health and Risk Management 2008:4(2) 276
Grigore et al
reported AEs in ezetimibe group then in the placebo group 
(63% vs 66%). The nature, number and pattern of occurencies 
of AEs that led to study discontinuation suggested no differ-
ential risk with ezetimibe treatment related to placebo; 3% of 
placebo and 4% of ezetimibe recipients discontinued due to 
AEs. Laboratory test results were generally similar between 
treatment groups. The incidence of elevated laboratory func-
tion test values (ALT and/or AST   3x the upper limit of 
normal (ULN) at two consecutive visits  1 week apart) was 
 1% in both placebo and ezetimibe treatment groups. Elevated 
muscle enzyme values (CK   10x ULN) were reported in less 
than 1% of groups. All the observed increases were asymptom-
atic and either transient with continued treatment or reversible 
following treatment discontinuation.
When associated with statins, approximately 95% 
of patients completed the treatment (Gagne et al 2002). 
Gastrointestinal system disorder was the most common AE 
leading to discontinuation, occurring in 1% of patients. In 
phase II and III studies of the statin plus ezetimibe group, 
20% of patients had what the investigator considered to 
be treatment-related AE compared to 17% in the group of 
patients receiving statin and placebo (10% of AE incidence 
was related to gastrointestinal system disorders). Elevation 
in either ALT or AST   3x ULN at two consecutive pos-
line measurements were similar in the two treatment groups 
(1% and  1% respectively). No case of rhabdomyolysis was 
reported in ether treatment group.
In the EASE study ezetimibe add-on to statin was well tol-
erated with a safety proﬁ  le comparable with placebo (Denke 
et al 2006). When adverse events were evaluated for each of 
statin groups (simvastatin, atorvastatin, and other), no par-
ticular pattern was found among patients receiving ezetimibe 
versus placebo for any adverse event category (Gagne et al 
2002). Results of additional measurements of safety revealed 
no evidence of any adverse effects of ezetimibe treatment 
compared with placebo relative to statin monotherapy. In 
general, there were no signiﬁ  cant differences between ezeti-
mibe/simvastatin and rosuvastatin (Catapano et al 2006) in 
terms of clinically signiﬁ  cant elevations in levels of muscle 
or liver enzymes. With regard to the liver enzymes ALT and 
AST, ezetimibe/simvastatin tended towards a numerically 
higher frequency of elevated levels, compared with rosuvas-
tatin, partially attributed to differences at the 10/80 mg and 
40 mg doses, but not at lower doses. Both study drugs were 
generally well tolerated. In conclusion, while the combina-
tion of ezetimibe with moderate doses of statins appears to 
be reasonably safe, the long-term safety of combination with 
high doses of statins remains to be established (Davidson 
et al 2007). More data are expected from the ongoing trials 
described below.
Ezetimibe, dyslipidemia and 
cardiovascular outcomes: future 
developments
Although treating two sources of cholesterol through dual 
inhibition provides superior LDL-C lowering efﬁ  cacy with 
improved LDL-C goal attainment, one key clinical question 
remains to be addressed: Do the lower LDL-C levels achieved 
with dual inhibition of cholesterol production and absorp-
tion ultimately translate into reduced cardiovascular or renal 
events and a slower rate of progression of atherosclerosis? 
This question is currently being assessed in several major 
cardiovascular outcomes studies, including Ezetimibe and 
Simvastatin in Hypercholesterolemia Enhances Athero-
sclerosis Regression (ENHANCE), Improved Reduction of 
Outcomes: Vytorin™ Efﬁ  cacy International Trial (IMPROVE 
IT), Simvastatin and Ezetimibe in Aortic Stenosis Study 
(SEAS), and Study of Heart and Renal Protection (SHARP). 
These major endpoint trials collectively involve more than 
21,000 patients.
More recently ezetimibe has been co-administered 
with fenofibrate in patients with mixed hyperlipidemia 
(McKenney et al 2006). Preliminary results after com-
pleting the 12-week randomized double-blind base study 
showed that the association of ezetimibe to fenoﬁ  brate 
produced signiﬁ  cantly greater reduction in LDL-C (−22% 
vs −9% respectively; p   0.001). There were also sig-
niﬁ  cantly improvements in TG, HDL, total cholesterol and 
non-HDL-C with fenoﬁ  brate + ezetimibe compared with 
fenoﬁ  brate alone. Overall fenoﬁ  brate plus ezetimibe was 
well tolerated and the proportion of patients with consecu-
tive elevations of ALT or AST   3x the normal limit was 
similar (1.2% fenoﬁ  brate + ezetmibe vs 1.7% fenobibrate 
alone). The efﬁ  cacy of the association of ezetimibe/simvas-
tatin 10/20 mg with fenoﬁ  brate 160 mg has been investigated 
in patients with mixed hyperlipidemia (Farnier et al 2007). 
LDL-C was signiﬁ  cantly reduced with eze/simva + feno 
(−45.8%) compared with feno (−15.7%) or placebo (−3.5%). 
Treatment with eze/simva + feno was generally well toler-
ated with a safety proﬁ  le similar to the eze/simva and feno 
therapies. Further studies are warranted to investigate the role 
of ezetimibe and ﬁ  brates in mixed dyslipidemia.
Conclusions
A wide therapeutic gap exists between target LDL-C levels and 
LDL-C levels typically achieved in actual clinical practice – a Vascular Health and Risk Management 2008:4(2) 277
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gap that will certainly widen with traditional therapy of single 
inhibition in light of recent amendments to the NCEP ATP 
III guidelines. The new aggressive cholesterol treatment goals 
call for a more advanced therapeutic approach to maximize the 
cardiovascular beneﬁ  ts associated with lower LDL-C levels. 
One logical approach is to target both cholesterol production 
in the liver and absorption in the intestine. By administrating 
ezetimibe/simvastatin as a single tablet or co-administering 
ezetimibe together with any dose of any statin, we can expect 
superior LDL-C-lowering efﬁ  cacy and a substantially greater 
proportion of patients achieving or getting below LDL-C treat-
ment goals. Treating two sources of cholesterol through dual 
inhibition should therefore be considered as a more advanced 
therapeutic option for all hypercholesterolemic patients whose 
LDL-C levels are not appropriately controlled approximately 
2–3 months after initiating statin monotherapy.
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